Ablation manual for liver cancer.

Hitoshi Maruyama, Yasunori Minami, Katsutoshi Sugimoto, Akihiro Funaoka, Kazushi Numata

Abstract readReview

In one paragraph

Review in Journal of medical ultrasonics (2001), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hitoshi MaruyamaDepartment of Gastroenterology, Juntendo University, 2-1-1 Hongo, Bunkyo, Tokyo, 113-8421, Japan. h.maruyama.tw@juntendo.ac.jp.ORCID http://orcid.org/0000-0003-3371-3157

Yasunori MinamiDepartment of Gastroenterology, Faculty of Medicine, Kindai University, Ohno-Higashi Osaka-Sayama, Osaka, 589-8511, Japan.

Katsutoshi SugimotoDepartment of Gastroenterology and Hepatology, Tokyo Medical University, 6-1-1 Shinjuku, Tokyo, 160-8402, Japan.

Akihiro FunaokaGastroenterological Center, Yokohama City University Medical Center, 4-57 Urafunecho, Minami, Yokohama, Kanagawa, 232-0024, Japan.

Kazushi NumataGastroenterological Center, Yokohama City University Medical Center, 4-57 Urafunecho, Minami, Yokohama, Kanagawa, 232-0024, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Because of recent advances in energy device technology, ablation has become popular worldwide. It is less invasive and provides faster postoperative recovery compared to surgery, and therefore, it has come to be applied to a wide range of organs, such as liver, lung, kidney, thyroid, and bone/soft tissue tumors. In order to properly guide the needle to the target area, imaging support is necessary, and ultrasound, which has the advantages of high resolution and real-time capability, is the most frequently used modality. In other words, ablation can be said to be a therapeutic method that makes the most of the advantages of ultrasound. This article outlines the role of ultrasound in ablation for liver cancer and its specific usage.

Indexed as

Ablation TechniquesLiver NeoplasmsUltrasonography, InterventionalHumansAblationCancerHepatocellular carcinomaLiverUltrasound

Identifiers

PMID39395134

DOI10.1007/s10396-024-01499-9

PMCPMC11799107

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.